18018 Federal Register / Vol. 87, No. 60 / Tuesday, March 29, 2022 / Notices 

owned by the bank holding company, 

including the companies listed below. 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in the BHC Act 

(12 U.S.C. 1842(c)). 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than April 28, 2022. 

A. Federal Reserve Bank of Boston 

(Prabal Chakrabarti, Senior Vice 

President) 600 Atlantic Avenue, Boston, 

Massachusetts 02210–2204. Comments 

can also be sent electronically to 

BOS.SRC.Applications.Comments@

bos.frb.org: 

1. 1854 Bancorp, Cambridge, 

Massachusetts; to acquire Patriot 

Community Bank, Woburn, 

Massachusetts. 

Board of Governors of the Federal Reserve 

System, March 24, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–06585 Filed 3–28–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Supplemental Evidence and Data 

Request on Postpartum Home Blood 

Pressure Monitoring, Postpartum 

Treatment of Hypertensive Disorders 

of Pregnancy, and Peripartum 

Magnesium Sulfate Regimens for 

Preeclampsia With Severe Features 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for supplemental 

evidence and data submissions. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

scientific information submissions from 

the public. Scientific information is 

being solicited to inform our review on 

Postpartum Home Blood Pressure 

Monitoring, Postpartum Treatment of 

Hypertensive Disorders of Pregnancy, 

and Peripartum Magnesium Sulfate 

Regimens for Preeclampsia With Severe 

Features, which is currently being 

conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program. 

Access to published and unpublished 

pertinent scientific information will 

improve the quality of this review. 

DATES: Submission Deadline on or 

before April 28, 2022. 

ADDRESSES: 

Email submissions: epc@

ahrq.hhs.gov. 

Print submissions: 

Mailing Address: Center for Evidence 

and Practice Improvement, Agency for 

Healthcare Research and Quality, 

ATTN: EPC SEADs Coordinator, 5600 

Fishers Lane, Mail Stop 06E53A, 

Rockville, MD 20857. 

Shipping Address (FedEx, UPS, etc.): 

Center for Evidence and Practice 

Improvement, Agency for Healthcare 

Research and Quality, ATTN: EPC 

SEADs Coordinator, 5600 Fishers Lane, 

Mail Stop 06E77D, Rockville, MD 

20857. 

FOR FURTHER INFORMATION CONTACT: 

Jenae Benns, Telephone: 301–427–1496 

or Email: epc@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency for Healthcare Research and 

Quality has commissioned the 

Evidence-based Practice Centers (EPC) 

Program to complete a review of the 

evidence for Postpartum Home Blood 

Pressure Monitoring, Postpartum 

Treatment of Hypertensive Disorders of 

Pregnancy, and Peripartum Magnesium 

Sulfate Regimens for Preeclampsia With 

Severe Features. AHRQ is conducting 

this systematic review pursuant to 

Section 902 of the Public Health Service 

Act, 42 U.S.C. 299a. 

The EPC Program is dedicated to 

identifying as many studies as possible 

that are relevant to the questions for 

each of its reviews. In order to do so, we 

are supplementing the usual manual 

and electronic database searches of the 

literature by requesting information 

from the public (e.g., details of studies 

conducted). We are looking for studies 

that report on Postpartum Home Blood 

Pressure Monitoring, Postpartum 

Treatment of Hypertensive Disorders of 

Pregnancy, and Peripartum Magnesium 

Sulfate Regimens for Preeclampsia With 

Severe Features, including those that 

describe adverse events. The entire 

research protocol is available online at: 

https://effectivehealthcare.ahrq.gov/ 

products/hypertensive-disorderspregnancy/protocol. 

This is to notify the public that the 

EPC Program would find the following 

information on Postpartum Home Blood 

Pressure Monitoring, Postpartum 

Treatment of Hypertensive Disorders of 

Pregnancy, and Peripartum Magnesium 

Sulfate Regimens for Preeclampsia With 

Severe Features helpful: 

D A list of completed studies that 

your organization has sponsored for this 

indication. In the list, please indicate 

whether results are available on 

ClinicalTrials.gov along with the 

ClinicalTrials.gov trial number. 

D For completed studies that do not 

have results on ClinicalTrials.gov, a 

summary, including the following 

elements: Study number, study period, 

design, methodology, indication and 

diagnosis, proper use instructions, 

inclusion and exclusion criteria, 

primary and secondary outcomes, 

baseline characteristics, number of 

patients screened/eligible/enrolled/lost 

to follow-up/withdrawn/analyzed, 

effectiveness/efficacy, and safety results. 

D A list of ongoing studies that your 

organization has sponsored for this 

indication. In the list, please provide the 

ClinicalTrials.gov trial number or, if the 

trial is not registered, the protocol for 

the study including a study number, the 

study period, design, methodology, 

indication and diagnosis, proper use 

instructions, inclusion and exclusion 

criteria, and primary and secondary 

outcomes. 

D Description of whether the above 

studies constitute ALL Phase II and 

above clinical trials sponsored by your 

organization for this indication and an 

index outlining the relevant information 

in each submitted file. 

Your contribution is very beneficial to 

the Program. Materials submitted must 

be publicly available or able to be made 

public. Materials that are considered 

confidential; marketing materials; study 

types not included in the review; or 

information on indications not included 

in the review cannot be used by the EPC 

Program. This is a voluntary request for 

information, and all costs for complying 

with this request must be borne by the 

submitter. 

The draft of this review will be posted 

on AHRQ’s EPC Program website and 

available for public comment for a 

period of 4 weeks. If you would like to 

be notified when the draft is posted, 

please sign up for the email list at: 

https://www.effectivehealthcare.

ahrq.gov/email-updates. 

The systematic review will answer the 

following questions. This information is 

provided as background. AHRQ is not 

requesting that the public provide 

answers to these questions. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 60 / Tuesday, March 29, 2022 / Notices 18019 

Key Questions (KQ) 

KQ 1: What are the effectiveness, 

comparative effectiveness, and harms of 

home blood pressure monitoring/ 

telemonitoring in postpartum 

individuals? 

KQ 2: What are the effectiveness, 

comparative effectiveness, and harms of 

pharmacological treatments for 

hypertensive disorders of pregnancy in 

postpartum individuals? 

KQ 3: What are the comparative 

effectiveness and harms of alternative 

magnesium sulfate (MgSO4) treatment 

regimens to treat preeclampsia with 

severe features during the peripartum 

period? 

3.a. Are there harms associated with 

the concomitant use of particular 

antihypertensive medications during 

treatment with MgSO4? 

For all Key Questions, how do the 

findings vary by race, ethnicity, HDP 

subgroup, maternal age, parity, 

singleton/multiple pregnancies, mode of 

delivery, co-occurring conditions (e.g., 

obesity), and social determinants of 

health (e.g., postpartum insurance 

coverage, English proficiency, income, 

educational attainment)? 

Contextual Question (CQ) 

CQ 1: How are race, ethnicity, and 

social determinants of health related to 

disparities associated with incidence of 

HDP, detection, access to care, 

management, followup care, and 

clinical outcomes in individuals with 

postpartum hypertensive disorders of 

pregnancy? 

Study Eligibility Criteria 

Key Question 1 (Home BP Monitoring) 

Population 

• Postpartum individuals (with or 

without a prior HDP diagnosis) 

Modifiers/Subgroups of Interest 

• Subgroups defined by ACOG HDP 

classification (some of which may 

arise de novo in the postpartum 

period) 

Æ chronic HTN 

Æ gestational HTN 

Æ preeclampsia (may be 

superimposed on chronic HTN) 

Æ preeclampsia with severe features 

(as defined by study authors) 

Æ de novo HTN postpartum 

• Subgroups defined by BP diagnostic 

threshold(s) 

• Race, ethnicity 

• Maternal age, parity, singleton/ 

multiple pregnancy, delivery (e.g., 

cesarean versus vaginal delivery, 

preterm versus term) 

• Co-occurring disorders (e.g., obesity, 

diabetes) 

• Subgroups defined by potential 

indicators of social determinants of 

health (e.g., insurance coverage, 

English proficiency, income, 

educational attainment) 

• Access to technology (e.g., broadband 

internet, smartphone) 

Interventions and Intervention 

Components 

• Postpartum home BP monitoring 

interventions 

Æ Electronic, digital monitors, any 

Æ With or without web-based 

connectivity and communication 

Æ With or without education or 

training in use of monitor 

Æ With or without validation of 

accuracy of patient’s monitor 

• Exclude: Ambulatory BP monitoring 

(e.g.,24- or 48-hour continuous 

monitoring) 

• Exclude: Monitors with manual 

inflation and auscultation 

• Exclude: BP monitoring only by third 

parties, such as home health aides, 

visiting nurses 

• Exclude: Very limited use of 

monitoring (e.g., single reading or 

single day) 

• Exclude: Use of device only in 

laboratory or clinic setting 

Comparators 

• No home BP monitoring (e.g., usual 

care with clinic-only BP monitoring) 

• Alternative non-clinic-based BP 

monitoring approaches (e.g., kiosks, 

pharmacy-based BP monitoring, home 

health aide visits) 

• Alternative education modalities 

about self-monitoring BP (e.g., 

demonstration of correct use, 

confirmation of appropriate cuff size) 

• Alternative home BP monitor 

characteristics (e.g., direct 

transmission of results, prompts for 

communication of symptoms) 

• Alternative home BP monitoring 

regimen (e.g., BP measurement 

frequency, duration) 

• Alternative instructions for when to 

communicate results immediately 

(e.g., different BP threshold alerts) 

• Alternative mode of communicating 

results (e.g., during clinic visit, 

automatic web-based, via text/email/ 

portal/phone) 

• Alternative clinician feedback 

processes 

• No use of validation of accuracy of 

patient’s monitor 

Outcomes (prioritized outcomes have an 

asterisk and are in bold font) 

• Blood pressure 

Æ Ascertainment of elevated BP or 

new onset HDP * 

D Time to clinical recognition of 

elevated BP 

Æ Treatment * 

D Initiation or discontinuation of 

antihypertensive medications 

D Increase or decrease in dose (or 

number) of antihypertensive 

medications 

D BP control (e.g., BP normalization) 

Æ Documentation of BP after 

discharge 

Æ Recognition of white coat HTN 

• Severe maternal outcomes 

Æ Maternal mortality, including 

pregnancy-related mortality * 

Æ Severe maternal morbidity * (e.g., 

stroke *, eclampsia, pulmonary 

edema) 

• Patient reported outcomes 

Æ Patient reported experience 

measures (PREMs) for example 

D Satisfaction with postpartum care * 

D Ease of access to care 

D Quality of communication 

D Support to manage HTN 

D Patient Reported Experience 

Measure of Obstetric racism 

(PREM–OB Scale) 

Æ Patient reported outcome measures 

(PROMs), for example 

D Global Quality of life *, e.g., SF–36 

D Psychosocial distress 

• Anxiety *, e.g., State-Trait Anxiety 

Inventory (STAI) 

• Depression *, e.g., Edinburgh 

Postnatal Depression Score (EPDS) 

• Healthcare utilization 

Æ Length of postpartum hospital 

stay * 

Æ Unplanned obstetrical triage area 

or clinic visits * 

Æ Emergency department visits * 

Æ Re-hospitalization after discharge * 

• Reduction of health disparities * 

(increase in disparities included 

under Harms) 

• Other Harms 

Æ Generation or exacerbation of 

health disparities * 

Æ Anxiety associated with use of 

monitoring technology 

Study Design 

• Comparative studies (comparisons of 

different interventions or regimens) 

Æ Randomized controlled trials (N 

≥10 per group) 

Æ Nonrandomized comparative 

studies (prospective or 

retrospective) that use statistical 

techniques (e.g., regression 

adjustment, propensity score 

matching, inverse probability 

weighting) to reduce bias due to 

confounding) 

• Any publication language (unless 

cannot be translated) 

• Exclude 

Æ Single group (noncomparative) 

studies 


lotter on DSK11XQN23PROD with NOTICES1
18020 Federal Register / Vol. 87, No. 60 / Tuesday, March 29, 2022 / Notices 

Æ Case-control studies 

Æ Claims database analyses 

Æ Feasibility studies 

Æ Device validation studies (not 

including validation of patients’ 

monitors in the clinic) 

Æ Qualitative studies 

Æ Conference abstracts prior to 2020 

(without subsequent, eligible peerreviewed publication) 

Timing 

• Intervention: Day of birth through 1 

year postpartum 

Æ Self-monitoring may start antenatal, 

in hospital, or postpartum, but must 

continue postpartum 

• Outcomes: Any (postpartum) 

Setting 

• Outpatient postpartum management 

(although training and initiation may 

start in hospital or at clinic) 

• Any publication date 

• Any country 

Key Question 2 (Treatment of HDP) 

Population 

• Postpartum individuals with 

diagnosed HDP (whether diagnosed 

antenatal, peripartum, or postpartum) 

Modifiers/Subgroups of Interest 

• Subgroups defined by ACOG HDP 

classification (these may arise de novo 

in the postpartum period) 

Æ chronic HTN 

Æ gestational HTN 

Æ preeclampsia (may be 

superimposed on chronic HTN) 

Æ preeclampsia with severe features 

(as defined by study authors) 

Æ de novo HTN postpartum 

• Subgroups defined by BP thresholds/ 

categories 

• Race, ethnicity 

• Maternal age, parity, singleton/ 

multiple pregnancy, mode of delivery 

(e.g., cesarean versus vaginal delivery, 

preterm versus term) 

• Co-occurring disorders (e.g., obesity, 

diabetes) 

• Subgroups defined by potential 

indicators of social determinants of 

health (e.g., insurance coverage, 

English proficiency, income, 

educational attainment) 

• Use of home monitoring 

Interventions 

• Pharmacological treatments for HTN 

or HDP administered postpartum 

Æ Antihypertensive medications 

(single or combination therapies) 

Æ Loop diuretics (alone or in 

combination with antihypertensive 

medications) 

• Exclude: 

Æ Medication not available for use in 

the U.S. 

Æ Nonpharmacological treatments 

(e.g., uterine curettage) 

Æ Corticosteroids (e.g., for HELLP) 

Æ Interventions to prevent 

preeclampsia (e.g., low-dose 

aspirin) 

Æ Treatments not used to treat HDP 

(e.g., NSAIDs) 

Æ Behavioral modification (e.g., diet, 

exercise) 

Æ Non-medical interventions (e.g., 

traditional medicine, 

complementary and alternative 

medicine, meditation, mindfulness) 

Comparators 

• Alternative specific treatments (e.g., 

alternative antihypertensive 

medication(s) or combinations of 

medications, alternative diuretic) 

• Alternative treatment regimen (e.g., 

alternative dose, duration of 

treatment) 

• Alternative blood pressure targets 

• No treatment (or placebo) 

• Exclude: Excluded interventions 

Outcomes (prioritized outcomes have an 

asterisk and are in bold font) 

• Intermediate outcomes 

Æ Blood pressure control * 

Æ Measures of end-organ function 

D Cardiovascular measures (e.g., 

echocardiographic measurements of 

diastolic function and hypertrophy) 

D Kidney function (e.g., estimated 

glomerular filtration rate) 

• Severe maternal outcomes 

Æ Maternal mortality, including 

pregnancy-related mortality * 

Æ Severe maternal morbidity * (e.g., 

stroke *, eclampsia, pulmonary 

edema) 

• Patient reported outcomes 

Æ Patient reported experience 

measures (PREMs), for example 

D Satisfaction with postpartum care * 

D Ease of access to care 

D Quality of communication 

D Support to manage HTN 

Æ Patient reported outcome measures 

(PROMs), for example 

D Global Quality of life *, e.g., SF–36 

D Maternal-neonatal bonding, e.g., 

Postpartum Bonding Questionnaire 

D Psychosocial distress 

• Anxiety *, e.g., State-Trait Anxiety 

Inventory (STAI) 

• Depression *, e.g., Edinburgh 

Postnatal Depression Score (EPDS) 

• Healthcare utilization 

Æ Length of postpartum hospital 

stay * 

Æ Unplanned obstetrical triage area 

or clinic visits * 

Æ Emergency department visits * 

Æ Re-hospitalization after discharge * 

• Infant health outcomes 

Æ Breastfeeding outcomes (e.g., 

initiation, success, duration) * 

• Reduction of health disparities * 

(increase in disparities included 

under Harms) 

• Harms 

Æ Severe adverse events * (e.g., 

electrolyte abnormalities, severe 

hypotension) 

Æ Infant morbidities * (e.g., 

hypotension, other symptoms 

attributed to medication exposure 

via breast milk) 

Æ Generation or exacerbation of 

health disparities * 

Æ Adverse interactions with other 

medications 

Study Design 

• Comparative studies (comparisons of 

different interventions or regimens) 

Æ Randomized controlled trials (N 

≥10 per group) 

Æ Nonrandomized comparative 

studies (prospective or 

retrospective) that use statistical 

techniques (e.g., regression 

adjustment, propensity score 

matching, inverse probability 

weighting) to reduce bias due to 

confounding 

• Any publication language (unless 

cannot be translated) 

• Exclude 

Æ Single group (noncomparative) 

studies 

Æ Case-control studies 

Æ Claims database analyses 

Æ Feasibility studies 

Æ Qualitative studies 

Æ Conference abstracts prior to 2020 

(without subsequent, eligible peerreviewed publication) 

Timing 

• Intervention: Day of birth up to 1 year 

postpartum 

Æ Intervention may start antenatal, in 

hospital, or postpartum, but must 

continue postpartum 

• Outcomes: Any (postpartum) 

Setting 

• Outpatient, non-acute management 

(treatment may start inpatient) 

• Any publication date 

• Any country 

Key Question 3 (MgSO4 for 

Preeclampsia With Severe Features) 

Population 

• Individuals who have preeclampsia 

with severe features (as defined by 

study authors) during the peripartum 

period (prior to and/or after delivery) 

• Exclude: Pregnant patients who are 

treated with MgSO4 with the goal of 

suppressing premature labor, for fetal 

neuroprotection, or for other reasons 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 60 / Tuesday, March 29, 2022 / Notices 18021 

Modifiers/Subgroups of Interest 

• Race, ethnicity 

• Maternal age, parity, singleton/ 

multiple pregnancy, mode of delivery 

(e.g., cesarean versus vaginal delivery, 

preterm versus term) 

• Co-occurring disorders (e.g., obesity, 

diabetes) 

• Subgroups defined by potential 

indicators of social determinants of 

health (e.g., insurance coverage, 

English proficiency, income, 

educational attainment) 

• Timing of MgSO4 administration or 

onset of preeclampsia with severe 

features with respect to delivery 

Æ Antepartum 

Æ Intrapartum 

Æ Postpartum 

• Individuals with reduced kidney 

function 

Interventions 

• Peripartum MgSO4 administration 

Æ Any dose, route (except oral), 

timing, duration of treatment, 

concomitant treatment, or regimen 

• Exclude: Oral magnesium 

supplementation 

Comparators 

• Alternative MgSO4 regimens 

Æ Different criteria for initiation of 

treatment 

Æ Different criteria for stopping (or 

continuing) treatment 

Æ Different criteria for altering dosing 

during treatment 

Æ Different loading dose 

Æ Different planned total dose 

Æ Different route 

Æ Different planned duration of 

treatment 

Æ Tailored interventions based on 

pharmacokinetic monitoring (i.e., 

based on serum Mg levels) 

Æ Combined treatment with 

antihypertensive medications 

(including regimens with 

alternative antihypertensive 

medications) 

Æ Other variations in regimens 

• Exclude: No MgSO4 treatment (either 

placebo, no treatment, or non-MgSO4

comparators) 

Æ Except retain RCTs with placebo, 

no treatment, or non-MgSO4

comparators and NRCSs comparing 

MgSO4 with no MgSO4 for 

postpartum preeclampsia with 

severe features These may be 

included in network meta-analyses 

to indirectly compare alternative 

MgSO4 regimens. 

Outcomes (prioritized outcomes have an 

asterisk and are in bold font) 

• Severe maternal health outcomes 

Æ Maternal mortality, including 

pregnancy-related mortality * 

Æ Severe maternal morbidity * (e.g., 

eclampsia *, stroke) 

• Newborn/child outcomes 

Æ Infant morbidities * (e.g., 

respiratory depression, Apgar score) 

Æ Breastfeeding outcomes * (e.g., 

initiation, success, duration) 

Æ Fetal/neonatal mortality 

Æ Cognitive function 

• Healthcare utilization and functional 

status 

Æ Length of postpartum hospital stay 

Æ Time to ambulation 

• Patient reported outcomes 

Æ Patient reported experience 

measures (PREMs), for example 

D Satisfaction with care * 

D Quality of communication 

D Support to manage preeclampsia 

treatment 

Æ Patient reported outcome measures 

(PROMs), for example 

D Global Quality of life *, e.g., SF–36 

D Specific to postpartum 

population*, e.g., Mother-Generated 

Index, Functional Status After 

Childbirth scales 

D Psychosocial distress 

• Anxiety *, e.g., State-Trait Anxiety 

Inventory (STAI) 

• Depression *, e.g., Edinburgh 

Postnatal Depression Score (EPDS) 

• Stress *, e.g., Impact of Event Scale 

D Maternal-neonatal bonding *, e.g., 

Postpartum Bonding Questionnaire 

• Reduction of health disparities * 

(increase in disparities included 

under Harms) 

• Maternal harms/adverse events 

Æ Magnesium-related toxicity * 

(respiratory depression, loss of 

reflexes, reduced urine output, need 

for calcium infusion) * 

Æ Other clinically important adverse 

events* (e.g., hypotension, 

neuromuscular blockade) 

Æ Adverse drug interactions * (e.g., 

with antihypertensive medications) 

Æ Generation or exacerbation of 

health disparities * 

Æ Other serious (e.g., severe flushing) 

Study Design 

• Comparative studies (comparisons of 

different interventions) 

Æ Randomized controlled trials N ≥10 

per group 

D Comparisons between MgSO4 and 

placebo/no treatment or non-MgSO4

treatments must be randomized (for 

potential network meta-analyses) 

Æ Nonrandomized comparative 

studies (prospective or 

retrospective) that use statistical 

techniques (e.g., regression 

adjustment, propensity score 

matching, inverse probability 

weighting) to reduce bias due to 

confounding 

• Any publication language (unless 

cannot be translated) 

• Exclude 

Æ Single group (noncomparative) 

studies 

Æ Case-control studies 

Æ Claims database analyses 

Æ Feasibility studies 

Æ Qualitative studies 

Æ Conference abstracts prior to 2020 

(without subsequent, eligible peerreviewed publication) 

Timing 

• Intervention: Peripartum (antenatal, 

during delivery hospitalization, 

postpartum) 

• Outcomes: Any 

Setting 

• Inpatient management 

• Any publication date 

• Any country 

Dated: March 23, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–06532 Filed 3–28–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Meeting of the National Advisory 

Council for Healthcare Research and 

Quality 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ). 

ACTION: Notice of public meeting. 

SUMMARY: This notice announces a 

meeting of the National Advisory 

Council for Healthcare Research and 

Quality. 

DATES: The meeting will be held on 

Thursday, May 12, 2022, from 10:00 

a.m. to 3:00 p.m. 

ADDRESSES: The meeting will be held 

virtually. 

FOR FURTHER INFORMATION CONTACT: 

Jaime Zimmerman, Designated 

Management Official, at the Agency for 

Healthcare Research and Quality, 5600 

Fishers Lane, Mail Stop 06E37A, 

Rockville, Maryland 20857, (301) 427– 

1456. For press-related information, 

please contact Bruce Seeman at (301) 

427–1998 or Bruce.Seeman@

AHRQ.hhs.gov. 

Closed captioning will be provided 

during the meeting. If another 

reasonable accommodation for a 

disability is needed, please contact the 


lotter on DSK11XQN23PROD with NOTICES1